news & insights
Advancing the future of oncology through data, science, and discovery.
Stay up to date on how Pathos AI is transforming oncology drug development — from major funding milestones and clinical advancements to industry collaborations that shape the future of biopharma.
May 6, 2026
Transaction marks one of the first clinical-stage oncology acquisitions sourced, evaluated, and executed through an AI-powered drug development platform
Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
May 15, 2025
New York, NY, May 15th, 2025 (GLOBE NEWSWIRE) — Pathos AI, ( www.pathos.com ), a leading AI-driven biotech company applying cutting-edge artificial intelligence to drug development, today announced its $365 million Series D financing, bringing its post-money valuation to approximately $1.6 billion. This financing marks a major milestone for Pathos as it expands its AI-enabled platform to drive greater speed, precision, and success in oncology drug development. The proceeds will support advancement of the company’s clinical-stage pipeline and continued investment in its proprietary AI Foundation Model purpose-built for oncology. As part of this next phase, Pathos is developing the largest multimodal foundation model in oncology. This groundbreaking effort leverages deep clinical, molecular, and imaging data to improve clinical asset selection, clinical trial design, biomarker discovery, and therapeutic innovation across the oncology landscape. “Pathos was founded to transform drug development by harnessing the full potential of multimodal data and AI,” said Iker Huerga, CEO of Pathos AI. “With this financing, we’re building one of the most advanced AI engines, designed to accelerate development, deepen clinical insight, and ensure the right therapies reach the patients who need them most.” Founded to accelerate innovation in oncology, Pathos is pioneering a new model for AI-enabled drug development. One that leverages multimodal data, advanced Artificial Intelligence, and deep clinical insight to bring new therapies to patients faster. With a strong focus on Artificial Intelligence, clinical development, and clinical execution, Pathos is committed to improving patient outcomes by accelerating the path from molecule to medicine.
May 8, 2025
New York, NY, May 8th, 2025 (GLOBE NEWSWIRE) — Pathos AI, (www.pathos.com), a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief Executive Officer and Board Member. Huerga brings over two decades of experience at the intersection of artificial intelligence and oncology drug development. He was most recently Chief Data Scientist for Oncology R&D at AstraZeneca and formerly Executive Vice President at Tempus Labs. A repeat biotech entrepreneur, he has founded three oncology companies, with two successful exits. At Pathos, Huerga will lead the company’s next phase of growth as it scales its AI-driven platform to accelerate clinical success in oncology. “I’m thrilled to join Pathos at this pivotal moment,” said Huerga. “We’re building the first true AI-enabled drug development platform—one that prioritizes clinical outcomes, precision in patient selection, and speed to patients. With our unique multimodal data and AI capabilities, we believe Pathos can dramatically accelerate oncology drug development and bring new life to promising compounds that have been overlooked or deprioritized.” Under Huerga’s leadership, Pathos will expand its mission to integrate multimodal data, advanced artificial intelligence, and clinical insight into a next-generation platform for oncology innovation, accelerating the path from molecule to medicine for patients worldwide. As part of the leadership transition, Ryan Fukushima, who served as interim CEO, will take on a new role as Advisor and remain a Board Member. Pathos is pioneering a new model for AI-enabled drug development—one that leverages multimodal data, advanced artificial intelligence, and deep clinical insight to bring new therapies to patients faster. With a strong focus on Artificial Intelligence, clinical development, and clinical execution, Pathos is committed to improving patient outcomes by accelerating the path from molecule to medicine.
April 23, 2025
CHICAGO, April 23, 2025 — Pathos AI, Inc.(www.pathos.com), a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, today announced multi-year, strategic collaborations with AstraZeneca (LSE/STO/Nasdaq: AZN) and Tempus AI, Inc. (NASDAQ: TEM), in which the companies will work together to build a multimodal foundation model in oncology which can be used to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the broader oncology community. Pathos will use Tempus’ de-identified oncology data to build the foundation model. Upon completion, the model will be shared among all three parties to advance their individual efforts to improve patient care. The agreements include $200 million in data licensing and model development fees to Tempus. “As artificial intelligence becomes more prominent in drug discovery and development, the opportunity for companies like Pathos to build foundation models that seemed almost unimaginable a few years ago is now taking shape,” said Mohamad Makhzoumi, Co-CEO of NEA and Pathos Board Member. “We couldn’t be more excited to collaborate with Tempus and AstraZeneca given the potential of these models to improve patient outcomes.” “Generative AI and the emergence of large multimodal models is the final catalyst needed to usher in precision medicine in oncology at scale,” said Eric Lefkofsky, Founder and CEO of Tempus. “Tempus has spent the last decade investing billions of dollars into collecting the necessary data needed for a foundation model of this kind to take shape. We look forward to working with AstraZeneca and Pathos to apply AI-enabled solutions to advance therapies in an effort to help patients live longer and healthier lives.” “Cancer drug discovery and clinical development are being transformed by the ability to analyze vast amounts of rich data using artificial intelligence,” said Jorge Reis-Filho, Chief AI and Data Scientist, Oncology R&D, AstraZeneca. “We are excited to collaborate with Tempus and Pathos to advance our data and AI-driven R&D strategy through the development of a multimodal oncology foundation model that we believe will accelerate and increase the probability of clinical success across our diverse pipeline.”
the future of biopharma
Pathos is redefining what is possible in precision oncology.
see our pipeline
meet the team
